Laminar Pharma, founded by Professor Pablo Vicente Escribá, seeks to raise €7 million for its drug trial, LAM561, targeting glioblastoma. With phase III trials underway in...
Of the total amount that Laminar Pharma estimates it needs, $10.7 million (€10 million) correspond to bank financing already agreed with Banca March. In addition, the...